When working to help marginalized groups, especially the HIV community, Gilead Sciences knows it’s important to let the community take the lead.
That’s why the pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S. The money will be distributed through the campaign’s educational arm to support communities disproportionately affected by HIV, particularly communities of color.
Racism, homophobia and transphobia are a few barriers people in those communities face when trying to access HIV prevention and services. It’s especially difficult for Latino and Black men, who statistically face more challenging HIV odds. Research shows that one in two Black men who have sex with men and one in four Latino men who have sex with men will be diagnosed with HIV in their lifetimes.
“We’ve been in HIV for 30 years. We know that the only way to really have a sustained change is allowing the communities” to make the changes they want to see, “and the role that we play as a company is making the resources available,” Korab Zuka, Gilead’s VP of corporate giving, said.
The funding will focus on three areas. From a social justice standpoint, the aim is to tackle stigma and discrimination. It will also be used to engage the younger generation, made up of people who don’t have the same real-world perspective as older people who came of age during the AIDS epidemic and may not fully appreciate the impact of HIV.
The third goal of the funding is to improve inclusivity for the trans community. That’s a continuation of HRC’s Transgender Justice Initiative, a grassroots effort that works with trans organizations to improve public policy through education.
The HRC Fund plans to enlist some 30 historically Black colleges and universities to reach students with HIV education, prevention and treatment. Zuka previously worked with HRC over the years and knows the group’s strengths.
“HRC has the playbook and the toolkits that are necessary to really drive some of the sustained change,” he said.
Gilead has led the HIV PrEP market with blockbuster drug Truvada. However, Truvada, along with another HIV drug, Atripla, both lost patent protection in October. Gilead has strong follow-ups in both Descovy for PrEP and two-drug HIV med Biktarvy, which is already a blockbuster after two years on the market. Gilead reported total HIV portfolio sales of $16.9 billion for 2020, up 3% over the previous year non-pandemic 2019.
by Sharon Klahr Coey
Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).
Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).